Edition:
United Kingdom

Valeritas Holdings Inc (VLRX.OQ)

VLRX.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
4:50pm BST
Change (% chg)

$-0.04 (-3.81%)
Prev Close
$1.05
Open
$1.10
Day's High
$1.10
Day's Low
$1.00
Volume
6,681
Avg. Vol
131,938
52-wk High
$6.79
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Valeritas Announces V-Go Insulin Delivery Is Now Available In New Zealand
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Valeritas Holdings Inc ::VALERITAS ANNOUNCES THAT V-GO® INSULIN DELIVERY IS NOW AVAILABLE IN NEW ZEALAND.VALERITAS HOLDINGS INC - V-GO IS NOW AVAILABLE IN NEW ZEALAND THROUGH ITS EXCLUSIVE DISTRIBUTION AGREEMENT WITH NZMS DIABETES.VALERITAS HOLDINGS INC - NZMS DIABETES WILL BE RESPONSIBLE FOR SALES, MARKETING, CUSTOMER SUPPORT, AND DISTRIBUTION ACTIVITIES IN NEW ZEALAND.VALERITAS - CO WILL RETAIN RESPONSIBILITY FOR PRODUCT DEVELOPMENT, REGULATORY APPROVAL, AMONG OTHERS.  Full Article

Valeritas Announces V-Go Distribution Agreement In Austria And Germany
Monday, 21 May 2018 

May 21 (Reuters) - Valeritas Holdings Inc ::VALERITAS ANNOUNCES V-GO® DISTRIBUTION AGREEMENT IN AUSTRIA AND GERMANY.VALERITAS HOLDINGS INC - MED TRUST WILL HAVE RIGHTS TO PROMOTE, MARKET AND SELL V-GO TO DIABETES CLINICS AND PATIENTS IN AUSTRIA AND GERMANY.VALERITAS HOLDINGS - UNDER TERMS , MED TRUST WILL HAVE RIGHTS TO PROMOTE, MARKET AND SELL V-GO TO DIABETES CLINICS AND PATIENTS IN AUSTRIA, GERMANY.VALERITAS HOLDINGS INC - WILL RETAIN RESPONSIBILITY FOR PRODUCT DEVELOPMENT, REGULATORY APPROVAL, QUALITY MANAGEMENT, AND MANUFACTURING.  Full Article

Valeritas Announces Positive Results From Studies Testing Co's Insulin Delivery Device
Friday, 18 May 2018 

May 18 (Reuters) - Valeritas Holdings Inc ::VALERITAS ANNOUNCES POSITIVE CLINICAL RESULTS ACROSS TWO NEW STUDIES EVALUATING V-GO® WEARABLE INSULIN DELIVERY DEVICE IN PATIENTS WITH TYPE 2 DIABETES.VALERITAS HOLDINGS - IN TRIAL, AFTER THREE MONTHS OF V-GO USE, SIGNIFICANT REDUCTIONS WERE OBSERVED IN BOTH A1C AND TDD.VALERITAS HOLDINGS INC - IMPROVEMENTS IN A1C WERE NOTED ACROSS A WIDE RANGE OF BASELINE INSULIN DOSES IN TRIAL.  Full Article

Valeritas Sees Q4 Revenue About $5.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Valeritas Holdings Inc ::SAYS EXPECTS FULL YEAR 2017 REVENUE TO REACH $20 MILLION, IN LINE WITH PRIOR GUIDANCE.VALERITAS REPORTS PRELIMINARY FULL YEAR AND FOURTH QUARTER 2017 REVENUE RESULTS.SEES Q4 REVENUE ABOUT $5.6 MILLION.SEES Q4 REVENUE UP 16 PERCENT.  Full Article

Valeritas Holdings Files For Sale Of Up To 3.35 Mln Shares
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Valeritas Holdings Inc ::VALERITAS HOLDINGS INC FILES FOR SALE OF UP TO 3.35 MILLION SHARES OF CO'S COMMON STOCK BY ASPIRE CAPITAL FUND LLC - SEC FILING.  Full Article

Valeritas Q3 revenue rises 4 pct
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Valeritas Holdings Inc ::Valeritas reports third quarter 2017 financial results.Q3 revenue rose 4 percent to $5.1 million.Sees FY 2017 revenue $20 million.Valeritas Holdings Inc - ‍gross margin increased to 39.8% during Q3 of 2017 as compared to 35.6% during same period in 2016​.Valeritas Holdings Inc - ‍company expects continued improvement in efficiencies and gross margin to exceed 40% in Q4 of 2017​.  Full Article

BRIEF-Valeritas Qtrly Loss Per Share $1.72

* VALERITAS REPORTS RECORD FIRST QUARTER REVENUE WITH 32% YEAR-OVER-YEAR GROWTH AND GROSS MARGINS EXPAND TO RECORD 47.6%